true
Icon to close the modal
Support
Sales
Phone Icon
1.844.8.BD.LIFE (1.844.823.5433)
Submit a form online
Go next / move forward Icon
Modal Close Icon

Capability:

Product Line:

Icon to close thank you modal
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
Customer Service
Phone Icon
1.800.638.8663
technical_services@bd.com
Products

BD Onclarity™ HPV Assay

Extend the power of HPV testing

Contact Us
bd-onclarity-hpv-assay_CR_201200125
bd-onclarity-hpv-assay_CR_201168417
surepath_C_203148445
viper-lt-system_RC_DS_MD_202642155
bd-cor
Loading
Overview
false
Features and Benefits
Support risk stratification
Support risk stratification

Extended genotyping supports risk stratification and persistence monitoring to guide patient management1-5

Adapt to evolving screening guidelines
Adapt to evolving screening guidelines
The BD Onclarity™ HPV Assay offers the flexibility you need to adapt to changing screening guidelines and evolving patient management guidance.
Enhance patient management
Enhance patient management

Make more informed decisions with the extended genotyping information you need to assess each patient’s risk for confident follow-up decisions1-5

Genotype reporting
Genotype reporting

The BD Onclarity™ HPV assay reports individual results for 6 of the 14 high-risk genotypes and grouped results for the remaining 8 high-risk genotypes.12

Providing you with advanced accurate, timely detection and actionable HPV genotyping so you can make more informed decisions.
  • The BD Onclarity™ HPV assay is designed to minimize the risk of false-negative results by:
    • Including an internal cellular control, ensuring cellular material is present
    • Targeting the E6/E7 region of the HPV viral genome rather than the L1 region, which can be deleted during HPV DNA integration13
  • The BD Onclarity™ HPV assay is designed to minimize the rise of false-positive results by lacking cross-reactivity with low-risk HPV types12
  • Make more informed decisions with the extended genotyping information you need to assess each patient’s risk for confident follow-up decisions1-5

Products & Accessories

RELATED PRODUCTS NOT AVAILABLE
References
false
Resources
events.svg
Literature
BD's collection of literature on industry and on our offerings gives you information you can use to continue striving for excellence.
Learn more
Training-Icon.png
Training

BD offers training resources to help improve your clinical practices as part of our goal of advancing the world of health.

Learn more
events.svg
Events

BD supports the healthcare industry with market-leading products and services that aim to improve care while lowering costs. We host and take part in events that excel in advancing the world of health™.

Learn more
Case-Study-Icon.png
Case Studies
BD promotes clinical excellence by providing various resources on best practices, clinical innovations and industry trends in healthcare.
Learn more
References
false

References

  1. Stoler MH et al. Gynecol Oncol. 2019;153(1):26–33
  2. Bonde J et al. Int J Cancer. 2019; doi:10.1002/ijc.32291
  3. Elfgren K et al. Am J Obstet Gynecol. 2017;216(3):264.e1–264.e7.
  4. Radley D et al. Hum Vaccin Immunother. 2016;12(3):768–772.
  5. Bottari F et al. J Low Genit Tract Dis. 2019;23(1):39–42.
  6. WHO RHR. Cervical cancer, human papillomavirus (HPV), and HPV vaccines—key points for policy-makers and health professionals. WHO; 2007.
  7. Oliver SE et al. J Infect Dis. 2017;216(5):594–603.
  8. Drolet M et al. Lancet Infect Dis. 2015;15(5):565–580.
  9. Garland SM et al. Clin Infect Dis. 2016;63(4):519–527.
  10. Schiffman M et al. Gynecol Oncol. 2015;138(3):573–578.
  11. Schiffman M et al. Int J Cancer. 2016;139(11):2606–2615.
  12. BD OnclarityTM HPV Assay US Package Insert (8089899)
  13. Tjalma WAA et al. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):45–46.
true